Abstract 9P
Background
Breast cancer is identified as a leading cancer in Kyrgyz females. Poor diagnostic approaches lead to high rate of advanced breast cancer cases and consequently to a high mortality rate. Genetic testing is a promising method of prevention and early diagnosis of breast cancer.
Methods
This was a case-control study of 201 women of the Kyrgyz ethnic group with a morphologically verified breast cancer (N=99) and 102 controls age-matched with BC cases. The mean age of the patients was 48 years (minimum 24, maximum 74, STD=9.83). The extraction of DNA was carried out from venous blood. The genotyping was performed by using restriction fragment length polymorphism assay.
Results
Genotype CT of the polymorphic variant V353A HMMR gene has been defined as protective factor and decreases the risk of developing of breast cancer in the Kyrgyz population (OR=0,481, 95%CI 0,272 – 0,850, р=0,011). As well as combinations of the allele 194Trp (XRCC1 Arg194Trp) and genotype СТ (HMMR V353A) (OR=0,302, [95% CI 0,128-0,713], р=0,005), CT/TT (OR=0,459, 95% CI [0,259-0,814], р=0,007) of HMMR V353A and Palb2 T1100T (3300T>G)polymorphisms, CT/GG (OR=0,546, 95% CI [0,298-0,999], р=0,048) of HMMR V353A and TNF aG3080A polymorphisms are associated with decreased risk of developing of breast cancer in the Kyrgyz ethnic group. Furthermore, the allele 194Trp is associated with late age of diagnosis of breast cancer when comparing to 194Arg allele of XRCC1 gene (p=0,017), more often occurs in postmenopausal women (p=0,005) and in women with high BMI (>25) (p=0,003).
Conclusions
The above genotypes may be used as markers for evaluation of the risk of breast cancer in the Kyrgyz ethnic group.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
340TiP - A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection
Presenter: Shida Yan
Session: Poster display session
Resources:
Abstract
347P - Relationship between modified surgical margin and prognosis of cutaneous squamous cell carcinoma
Presenter: Yukiko Teramoto
Session: Poster display session
Resources:
Abstract
348P - Malignant melanoma: A study of clinical profiles and treatment outcomes in Indian patients
Presenter: Sorun Shishak
Session: Poster display session
Resources:
Abstract
349P - Flavonoids from ethanol extracts of euphorbia hirta inhibit melanoma growth and metastatic potential
Presenter: Shubhra Mishra
Session: Poster display session
Resources:
Abstract
350P - Low-dose cisplatin and 5-fluorouracil combined concurrent chemoradiotherapy for unresectable cutaneous squamous cell carcinoma: Analysis of 23 cases
Presenter: Azusa Hiura
Session: Poster display session
Resources:
Abstract
353P - A prediction model for the intents regarding life-sustaining treatment decisions in patients with terminal cancer
Presenter: Yoonsun Kim
Session: Poster display session
Resources:
Abstract
354P - Predictive factors and survival outcomes with stereotactic body radiation therapy in treatment of oligometastases in colorectal cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
355P - Cost analysis and overview of single versus multiple fraction palliative radiotherapy for painful bone metastasis
Presenter: Vinodhkumar Selvaraj
Session: Poster display session
Resources:
Abstract
356P - Observational study on role of crude cannabis in pain control and quality of life in terminally ill cancer patients: An Indian perspective
Presenter: Vidyasagar Dusi
Session: Poster display session
Resources:
Abstract